Agreement signed between Roche and Radiant to market life-saving drugs

One of the world's top research-based pharmaceutical companies based in Switzerland for the purpose of coordinating the treatment of serious diseases related to cancer, eye and brain complex problems in Bangladesh. An agreement has been signed between Hoffmann-La Roche and Radiant Pharmaceuticals Limited, one of the top 10 drug manufacturers in Bangladesh and a leading importer of specialty life-saving drugs.

The agreement was signed on Sunday (November 12) evening at a Radisson hotel in the capital.

Adriano Treve, Area Head for Central Eastern Europe, Turkey, Russia, and Indian Subcontinent, Roche was present at the event. While speaking, he mentioned the importance of starting this new collaboration relationship and said that it will open many new possibilities and make it easier for the patients of Bangladesh to get high-quality innovative medicines from Roche.

Chairman of Radiant Pharmaceuticals Limited Md.Nasser Shahriar Zahedi was also present at the event. He identified the launch of this joint marketing as a new milestone in the Bangladesh pharmaceutical industry. He further said that this new relationship through mutual trust and cooperation will benefit the pharmaceutical industry of Bangladesh as well as the country and its citizens in a larger sense.

To take this collaborative relationship a step further, Radiant and Roche have decided to launch a 'joint marketing' strategy to market cancer drugs. Through this, Roche and Radiant will work together to deliver Roche's high-quality drugs used in the treatment of cancer to patients in Bangladesh. Both companies said that the new collaboration will go a long way in improving global standards of cancer treatment in Bangladesh.

Mark Heeb, Country Manager of Roche Bangladesh and Sina Ibn Jamali, Managing Director of Radiant Pharmaceuticals Limited were also present on the occasion among others.